絞り込み

16733

広告

Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis.

著者 Lv F , Cai X , Yang W , Gao L , Chen L , Wu J , Ji L
Bone.2019 Oct 30 ; ():115121.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (76view , 1users)

Full Text Sources

Osteoporosis and cardiovascular (CV) diseases are closely correlated. RANKL/RANK/OPG pathway and Wnt signalling pathway both implicated in the pathogenesis of osteoporosis and cardiovascular diseases. We aimed to investigate the effect of denosumab or romosozumab therapy on cardiovascular outcomes in patients with primary osteoporosis.
PMID: 31678488 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード